RPRX · Royalty Pharma plc

$58.83 -0.19 (-0.32%) At close · Jul 24

Market Cap

$33.88B

575.83M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$2.38B +5.1%

FY2025

Net Income

$770.95M -10.2%

FY2025

Operating Margin

65.58% +8.5pp

FY2025

Diluted EPS

$1.78 -6.8%

FY2025

Operating Cash Flow

$2.49B -10.1%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	+2.1%	+2.3%	—	$2.44B	$2.38B^G	$2.26B	$2.35B	$2.24B	$2.29B	$2.12B
Research & Development	+36.7%	+76.6%	—	$441.29M	$452M	$2M	$52M	$177.11M	$200.08M	$26.29M
General & Administrative	+36.1%	+25.8%	—	$622.27M	$573.48M	$236.67M	$249.75M	$227.3M	$182.83M	$181.72M
Amortization of Intangibles	—	—	—	—	—	$0	$0	$5.67M	$23M	$23.06M
Total Costs & Expenses	-24.9%	+9.2%	—	$852.15M	$818.68M	$971.13M	$862.4M	$1.93B	$858.75M	$526.95M
Operating Income	+71.9%	-0.5%	—	$1.59B	$1.56B	$1.29B	$1.49B	$307.07M	$1.43B	$1.6B
Operating Margin	—	—	—	—	65.58%	57.1%	63.37%	13.73%	62.49%	75.17%
Interest Expense	+17.9%	+14.4%	—	$336.13M	$307.66M	$225.51M	$187.19M	$187.96M	$166.14M	$157.06M
Other Non-Operating Income	—	—	—	-$230.36M	-$235.33M	$38.37M	$207.94M	-$77M	-$189.51M	$106.56M
Equity in Earnings of Unconsolidated Entities	—	-8.1%	—	$44.4M	$29.09M	$29.61M	$28.88M	-$8.97M	-$19.49M	$44.46M
Pretax Income	+79.2%	-4.9%	—	$1.36B	$1.32B	$1.33B	$1.7B	$230.06M	$1.24B	$1.7B
Income Tax	—	—	—	$0	$0	$0	$0	$0	$0	$0
Net Income	+162.1%	-4.6%	—	$826.29M	$770.95M	$858.98M	$1.13B	$42.83M	$619.73M	$975.04M
Net Margin	—	—	—	—	32.42%	37.95%	48.2%	1.91%	27.07%	45.94%
Net Income Attributable to Noncontrolling Interests	+43.5%	-5.3%	—	$531.73M	$553.25M	$471.83M	$565.25M	$187.23M	$621.47M	$726.91M
Net Income Available to Common Stockholders	+162.1%	+9.3%	—	$826.29M	$770.95M	$858.98M	$1.13B	$42.83M	$619.73M	$495.2M
Comprehensive Income	+12.9%	—	—	—	—	$858.98M	$1.13B	$25.21M	$597.58M	$1.03B
EPS (Basic) USD/shares	+161.6%	+6.3%	—	—	$1.79	$1.92	$2.54	$0.10	$1.49	$1.32
EPS (Diluted) USD/shares	+161.1%	+6.2%	—	—	$1.78	$1.91	$2.53	$0.10	$1.49	$1.32
Shares Outstanding (Basic Avg) shares	-0.6%	+2.7%	—	—	429.8M	448.19M	447.6M	437.96M	414.79M	375.44M
Shares Outstanding (Diluted Avg) shares	+8.8%	+8.5%	—	—	564.46M	594.11M	602.9M	437.97M	414.8M	375.46M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2020–FY2025: $1.76B in buybacks.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

17.31×

Biotechnology median 8.41×

EV/EBIT

26.60×

Biotechnology median 26.60×

P/E (TTM)

30.96×

Biotechnology median 7.07×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Financial Royalty Assets	$2,261,152,000	$2,149,422,000	$2,197,754,000	$2,125,096,000	$2,065,083,000	$1,959,975,000	$1,648,837,000	$1,524,816,000
Royalty Income Other	$117,041,000	$114,154,000	$156,800,000	$112,119,000	$53,132,000	$18,996,000	$19,642,000	$135,960,000
Intangible Royalty Assets	—	—	—	—	$171,248,000	$143,382,000	$145,775,000	$134,118,000

Key facts CIK 1802768 CUSIP G7709Q104 13F (30d) 111 filings 111 filers Visit website Investor relations